Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 known ✓ | P29475 | 4/20 | 0.48 |
| ▸ | NOS2 known ✓ | P35228 | 4/20 | 0.48 |
| ▸ | NOS3 known ✓ | P29474 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylamine SCHEMBL10635405 | 1.00 | LOXL2 (0.70) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL18138713 | 0.98 | LOXL2 (0.67) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL20593186 | 0.95 | LOXL2 (0.70) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL8071959 | 0.93 | LOXL2 (0.61) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL2841170 | 0.90 | LOXL2 (0.78) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL2841167 | 0.90 | LOXL2 (0.78) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL25352130 | 0.87 | LOXL2 (0.74) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL3188490 | 0.87 | LOXL2 (0.74) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL8464909 | 0.87 | LOXL2 (0.74) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Benzylamine SCHEMBL6429492 | 0.87 | LOXL2 (0.74) | LOXL2CYP1A2CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120073481-A | Application of ammonium salt containing acetate in perovskite thin film gain medium | 浙江大学 | 2025-05-30 | — | — | CN | claimed |
| US-20250368679-A1 | FORMATION OF AMIDINES | VANVELLER BRETT (US) | 2025-12-04 | — | — | US | disclosed |
| CN-120073481-A | Application of ammonium salt containing acetate in perovskite thin film gain medium | 浙江大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20240409577-A1 | FORMATION OF AMIDINES AND INTRAMOLECULAR REACTION THEREOF | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240300888-A1 | FORMATION OF AMIDINES AND INTRAMOLECULAR REACTION THEREOF | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
| CN-109695648-B | Friction material | 博格华纳公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11261201-B2 | TRNA synthetase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
| CN-105483749-B | The paired electrosynthesis method of thiocyanogen α, β the unsaturated carbonyl class compound of 3 amido 2 | 北京工业大学 | 2017-11-24 | — | — | CN | disclosed |
| US-5965619-A | ADMINISTERING AN INDENE DERIVATIVE OF GIVEN FORMULA, SUCH AS 1-(2,4,6-TRIMETHOXYBENZYLIDENE)-5-DIMETHYLAMINO-2-METHYL-3-INDENYL ACETIC ACID, TO TREAT PRECANCEROUS LESIONS SUCH AS COLONIC ADENOMATOUS POLYPS; SIDE EFFECT REDUCTION | CELL PATHWAYS INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5707994-A | USEFUL AS A PLATELET AGGREGATION INHIBITOR, CANCER METASTASIS INHIBITOR, WOUND HEALING AGENT OR A BONE RESORPTION INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| CN-1138322-A | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0725059-A1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-4075344-A | 3-ALKOXYISOQUINOLINES FOR HYPOTENSIVE AND VASODILATING EFFECTS | MEAD JOHNSON & COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
| US-4015006-A | 3(2H)-Isoquinolones therapeutic process | MEAD JOHNSON & COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | NOS1 1980/4885NOS2 2020/4885NOS3 2167/4885 |
| US-20240409577-A1 | FORMATION OF AMIDINES AND INTRAMOLECULAR REACTION THEREOF | H1-4, H1-0, H1-3 | NOS1 73/4885NOS2 137/4885NOS3 194/4885 |
| US-20250368679-A1 | FORMATION OF AMIDINES | H1-4, H1-2, H1-3 | NOS1 17/4885NOS2 78/4885NOS3 96/4885 |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | NOS1 1980/4885NOS2 2020/4885NOS3 2167/4885 |
| US-20240300888-A1 | FORMATION OF AMIDINES AND INTRAMOLECULAR REACTION THEREOF | SRM, TST, NISCH | NOS1 44/4885NOS2 79/4885NOS3 41/4885 |
| US-11261201-B2 | TRNA synthetase inhibitors | TRMT1, AARS1, GARS1 | NOS1 1980/4885NOS2 2020/4885NOS3 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.